SCHEMBL3571934

SCHEMBL3571934

CCON=Cc1ccc2[nH]c3c(cc(-c4ccc(OC)cc4OC)c(=O)n3C)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.38
▸ TEK Q02763 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.36
▸ MAPT P10636 4/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ POLB P06746 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ PSMD14 O00487 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ MPO P05164 3/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CRHR1 P34998 2/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ CRHBP P24387 1/20 0.34
▸ CRHR2 Q13324 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3571932 1.00 KDR (0.38) KDRTEKKDM4EMAPTKMT2A
SCHEMBL3567241 0.85 KDM4E (0.41) KDM4EMAPTKMT2AALDH1A1CYP1A2
SCHEMBL2386218 0.80 KDM4E (0.43) KDM4EMAPTKMT2AALDH1A1CYP1A2
SCHEMBL3570043 0.79 BRD4 (0.43) KDM4EMAPTKMT2APOLBALDH1A1
SCHEMBL3575910 0.78 MAPT (0.49) KDM4EMAPTKMT2APOLBALDH1A1
SCHEMBL3575075 0.76 CCNB2 (0.47) KDM4EMAPTKMT2AALDH1A1CYP1A2
SCHEMBL3579883 0.76 MEN1 (0.49) KDRKDM4EMAPTKMT2APOLB
SCHEMBL3566184 0.75 MAPT (0.47) KDM4EMAPTKMT2APOLBALDH1A1
SCHEMBL3577091 0.72 KMT2A (0.48) KDM4EMAPTKMT2APOLBALDH1A1
SCHEMBL2386231 0.70 ALDH1A1 (0.43) KDM4EMAPTKMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD KDR 1221/4885TEK 1218/4885KDM4E 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback